Volume 4, Issue 6, November 2016, Page: 62-67
Correlation Between Expressions of VEGF and CA-125 with Stage, Level of Differentiation and Histopathology Type of Epithelial Ovarian Cancer
Farid Abdullah, Department of Obstetric and Gynecology, Medical Faculty, Hasanuddin University, Makassar, Indonesia
Syahrul Rauf, Department of Obstetric and Gynecology, Medical Faculty, Hasanuddin University, Makassar, Indonesia
Nusratuddin Abdullah, Department of Obstetric and Gynecology, Medical Faculty, Hasanuddin University, Makassar, Indonesia
Maisuri T. Chalid, Department of Obstetric and Gynecology, Medical Faculty, Hasanuddin University, Makassar, Indonesia; Department of Biostatistic, Faculty of Public Health, Hasanuddin University, Makassar, Indonesia
Deviana S. Riu, Department of Obstetric and Gynecology, Medical Faculty, Hasanuddin University, Makassar, Indonesia
Upik A. Miskad, Department of Anatomical Pathology, Medical Faculty, Hasanuddin University, Makassar, Indonesia
Received: Dec. 4, 2016;       Accepted: Dec. 15, 2016;       Published: Jan. 10, 2017
DOI: 10.11648/j.jgo.20160406.16      View  3065      Downloads  132
Abstract
Cancer Antigen (CA-125) is a tumor marker used to detect ovarian cancer. This study aims to determine the relationship of VEGF expression and the levels of CA-125 on primary tumor associated with stage, degree of differentiation and histopathological types of epithelial ovarian cancer. This study is an observational study with a cross sectional design in Wahidin Sudirohusodo Hospital and some parts teaching hospital of Obstetrics and Gynecology began in August 2015 to February 2016. The population was all patients with epithelial ovarian cancer who were treated and underwent surgery at the hospital who met the inclusion criteria. The data were processed using SPSS with bivariate analysis Mann Whitney, Kruskal Wallis and Spearman's Rho. The result there were significant differences of VEGF expression in cell differentiation and histopathological type (p <0.05). There are significant differences in the levels of CA-125 with clinical stage, differentiation of cells and histopathological type (p <0.05). The expression of VEGF is getting stronger when the type of epithelial ovarian cancer is getting bad influence on the degree of cells differentiation and the histopathological type. CA-125 levels obtained increased at an advanced stage and degree of cells differentiation are bad for ovarian cancer. There is a positive correlation between the expression of VEGF and CA-125 levels in epithelial ovarian cancer but was not significantly different and the relationship is weak.
Keywords
VEGF, CA-125, Epithelial Ovarian Cancer
To cite this article
Farid Abdullah, Syahrul Rauf, Nusratuddin Abdullah, Maisuri T. Chalid, Deviana S. Riu, Upik A. Miskad, Correlation Between Expressions of VEGF and CA-125 with Stage, Level of Differentiation and Histopathology Type of Epithelial Ovarian Cancer, Journal of Gynecology and Obstetrics. Vol. 4, No. 6, 2016, pp. 62-67. doi: 10.11648/j.jgo.20160406.16
Copyright
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Lengyel. (2010). Ovarian Cancer Development and Metastasis. The American Journal of Pathology, Vol. 177, No. 3.
[2]
Yamamoto et al. (2007). Expression of Vascular Endothelial Growth Factor (VEGF) in Epithelial Ovarian Neoplasms: Correlation With Clinicopathology and Patient Survival, and Analysis of Serum VEGF Levels. British Journal of Cancer 76 (9), 1221-1227.
[3]
Spannuth et al. (2008). Angiogenesis as a Strategic Target for Ovarian Cancer Therapy. Nature Clinical Practice Oncology. Vol 5 no 4.
[4]
Gubbels et al. (2010). The Detection, Treatment, and Biology of Epithelial Ovarian Cancer. Journal of Ovarian Research., 3: 8
[5]
Amini et al. (2012). Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application. Hindawi Publishing Corporation. Journal of Oncology.
[6]
Rancouert et al. (2012). The Role of MUC 16 Mucin (CA 125) in the Pathogenesis of Ovarian Cancer. Intechopen.
[7]
Gorp et al. (2011). HE4 and CA-125 as a Diagnostic Test in Ovarian Cancer: Prospective Validation of The Risk of Ovarian Malignancy Algorithm. British Journal of Cancer.
[8]
Suh et al. (2012). Ovarian Cancer Biomarkers For Molecular Biosensors And Translational Medicine. Expert-Riview, 10, 1069-1083.
[9]
Sarojin et al. (2012). Early Detection Biomarker For Ovarian Cancer. Journal of oncology, 1-15.
[10]
Olson et al. (2008). Vascular Permeability Gene in Normal and Neoplastic Human Ovaries. Cancer research, 74, 276-80.
[11]
Smerdel et al. (2011). VEGF in the Development of Ovarian Malignancy. Clinical Ovarian Cancer, 4, 19-25.
[12]
Yu et al. (2013). The Prognostic Value of Vascular Endothelial Growth Factor in Ovarian Cancer; A Systematic Review and Meta Analysis. Gynecologic Oncology, 128. 391-396.
[13]
Landen et al. (2008). Early Events in The Pathogenesis of Epithelial Ovarian Cancer. J clint Oncol., 26. 995-1005.
[14]
Secord et al. (2007). Co-expression of Angiogenic Markers and Associations With Prognosis in Advanced Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study. Gynecologic Oncology, 105, 221-232.
[15]
Kurman et al. (2008). Early Detection and Treatment of Ovarian Cancer: Shifting From Early Stage to Minimal Volume of Disease Based on a New Model of Carcinogenesis. Am J Obstet Gynecol, 198, 351-356.
[16]
Colombo & Parma. (2006). Ovarian Cancer. European Institute of Oncology, Division of Gynecology, Ripamonti: Milan, Italy University Hospitals Leuven, Belgium, Istituto Nazionale per lo Studlo ela Curadei Tumori, Milan, Italy Istituto Oncologi codella Svizzera Italiana (IOSI), Bellinzona, Switzeland.
[17]
Hogdall et al. (2007). CA125 Expression Pattern, Prognosis and Correlation With Serum CA125 in Ovarian Tumor Patients From the Danish “MALOVA” Ovarian Cancer Study. Gynecol Oncol. 104: 508-515.
Browse journals by subject